The proton therapy market size in Europe is anticipated to grow from USD 183.07 million in 2023 to USD 41.54 million by 2028, growing at a CAGR of 17.93% from 2023 to 2028.
The increasing prevalence of cancer cases in the European region primarily drives the growth of the European proton therapy market. Cancer remains a leading cause of mortality in Europe, with millions of new cases reported annually. Lifestyle factors, hormonal changes, genetic predisposition and habits such as alcohol consumption and smoking contribute to the development of tumors and cancerous conditions. Among various treatment options available, proton therapy is gaining prominence due to its reduced side effects compared to other therapies. Healthcare providers recommend proton therapy for targeting and eliminating cancer cells with precision. This advanced therapy is particularly effective in treating cancers of the eye, head, neck, liver, prostate, and brain.
The rising awareness among the European population about the benefits of proton therapy promotes European market growth. The continuous advancements in the development of innovative proton therapies further drive the growth of the proton therapy market in Europe. Researchers are dedicated to enhancing the efficacy of proton therapy through the exploration of different radiation techniques tailored to specific cancer treatments. Medical device manufacturers are actively involved in the development of specialized equipment and devices for proton therapy. The growing support from the governments of European countries, increasing regulatory approvals and favorable reimbursement policies contribute to the growth of the European proton therapy market.
The high cost associated with proton therapy, challenges related to the availability of skilled professionals and infrastructure facilities primarily hinder the growth of the European proton therapy market growth. The lack of awareness among patients and healthcare providers, errors in dose calculation during treatment and potential side effects such as redness and skin burns further inhibit the growth rate of the European market.
This research report on the Europe proton therapy market has been segmented and sub-segmented into the following categories.
By Indication:
By Product:
By Type:
By Set-Up Systems:
By Application Type:
By End-User:
By Country:
The European region is anticipated to account for a substantial share of the global market during the forecast period and had a notable share of the European market in 2022. With approximately 80 proton therapy centers worldwide, around 30% of them are located in Europe. Germany led the proton therapy market in the European region in 2022 and is expected to grow at a healthy CAGR during the forecast period. The growing patient population and rapid adoption of advanced cancer treatments drive the German proton therapy market primarily. The initiatives from the German government in approving novel proton therapy further contribute to the domination of Germany in the European region. The establishment of numerous proton therapy hospitals and clinics, the availability of skilled physicians, and industry mergers favor the growth of the German market. The UK is anticipated to account for a notable share of the European market during the forecast period owing to the growing number of research centers, clinical trial facilities and increasing investment by the UK government in establishing proton therapy centers.
KEY MARKET PLAYERS:
Companies that play a leading role in the Europe proton therapy market are IBA (Ion Beam Applications SA), Varian Medical Systems, Inc., Hitachi, Ltd., Mevion Medical Systems, Inc. and ProTom International Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region